Communication Of Fidaxomicin's 30-Day Effect Is Question For Labeling Discussions
This article was originally published in The Pink Sheet Daily
Executive Summary
Anti-Infective Drugs Advisory Committee votes 13-0 to approve the antibiotic for treating Clostridium difficile, but rejects a claim for lowering the risk of recurrence, preferring focus on effect at 30 days.
You may also be interested in...
Optimer Looking At Prophylaxis As Next Frontier For C. Difficile Agent Dificid
Optimer's next step, having garnered the expected FDA approval of its Clostridium difficile antibiotic Dificid (fidaxomicin), will be to consider prophylaxis as a possible road to an expanded market for the macrolide antibiotic.
Optimer Looking At Prophylaxis As Next Frontier For C. Difficile Agent Dificid
Optimer's next step, having garnered the expected FDA approval of its Clostridium difficile antibiotic Dificid (fidaxomicin), will be to consider prophylaxis as a possible road to an expanded market for the macrolide antibiotic.
Labeling For Optimer's Dificid Includes Data On Ability To Sustain Cure Post-Treatment
FDA approves the macrolide antibacterial for treatment of Clostridium difficile-associated diarrhea.